12:00 AM
 | 
Jan 30, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Vytorin ezetimibe/simvastatin regulatory update

FDA did not approve new indications for 2 cholesterol drugs from Merck in chronic kidney disease (CKD) patients. According to the pharma, the agency did not approve the new indications for Vytorin ezetimibe/simvastatin and Zetia ezetimibe because the Phase III SHARP trial - which formed the basis of the sNDA...

Read the full 229 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >